West Pharmaceutical Services (WST) Non-Current Deferred Tax Liability (2009 - 2026)

West Pharmaceutical Services has disclosed Non-Current Deferred Tax Liability across 18 years of filings, most recently posting $22.7 million for Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $22.7 million, up 6.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.7 million (up 6.57% YoY), and the FY2025 annual result was $23.0 million, down 73.95% from the prior year.
• Non-Current Deferred Tax Liability came in at $22.7 million for Q1 2026 at West Pharmaceutical Services, down from $23.0 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $88.3 million in Q4 2024 to a low of $1.2 million in Q2 2022.
• The 5-year median for Non-Current Deferred Tax Liability is $16.6 million (2022), against an average of $27.6 million.
• Peak annual rise in Non-Current Deferred Tax Liability reached 1520.41% in 2022, while the deepest fall reached 90.16% in 2022.
• West Pharmaceutical Services' Non-Current Deferred Tax Liability stood at $79.4 million in 2022, then climbed by 7.3% to $85.2 million in 2023, then gained by 3.64% to $88.3 million in 2024, then tumbled by 73.95% to $23.0 million in 2025, then dropped by 1.3% to $22.7 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $22.7 million (Q1 2026), $23.0 million (Q4 2025), and $22.8 million (Q3 2025), per Business Quant data.